Efficacy analysis of five-year experience of vaccination with conjugate pneumococcal vaccine in patients with chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2018-28-2-185-192
Abstract
This study was aimed at analysis of 5-year clinical efficacy and pharmacoeconomic effectiveness of conjugate pneumococcal vaccine in patients with chronic obstructive pulmonary disease (COPD). Methods. Male patients with COPD (n = 394) were involved in the study. Primary endpoints were changes in MMRC score, FEV1, number of exacerbations and hospitalizations, and a rate of pneumonia. The BODE index was calculated. Drug therapy of all patients was analyzed. 13-valent conjugate pneumococcal vaccine PCV13 and 23-valent polysaccharide vaccine PPV23 were used for vaccination. Results. Vaccination with PCV13 resulted in improvement in dyspnea and lung function both for short-term and 5-year follow-up. Therefore, PCV13 could be considered as a part of the basic therapy along with bronchodilators. Vaccination with PCV-13 could reduce risk of unfavorable events in the course of COPD and improve the patients’ survival. Conclusion. Vaccination with PCV13 in patients with COPD could reduce number of exacerbations, incidence of pneumonia, and the need in healthcare resources due to maintaining the effect during 4 years. Budget savings could reach 409.9 million rubles per a year.
About the Authors
G. L. Ignatova
South Ural State Medical University, Healthcare Ministry of Russia
Russian Federation
Doctor of Medicine, Professor, Head of Department of Therapy, Institute of Postgraduate Physician Training
Russian Federation
Doctor of Medicine, Professor, Head of Department of Therapy, Institute of Postgraduate Physician Training
V. N. Antonov
South Ural State Medical University, Healthcare Ministry of Russia
Russian Federation
Candidate of Medicine, Associate Professor, Department of Therapy, Institute of Postgraduate Physician Training
Russian Federation
Candidate of Medicine, Associate Professor, Department of Therapy, Institute of Postgraduate Physician Training
References
1. GOLD 2011. Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2011. Available at: http://gold-copd.org/gold-2011-global-strategy-diagnosis-management-prevention-copd/ [Accessed 05 March, 2018].
2. GOLD 2017. Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2017. Available at: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ [Accessed 05 March, 2018].
3. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. at al. Federal clinical guidelines for diagnosis and treatment of chronic obstructive pulmonary disease. 2016. Available at: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ (in Russian).
4. ESC recommendations on the diagnosis and treatment of acute and chronic heart failure. 2016. Available at: http://www.scardio.ru/rekomendacii/rekomendacii_esc_close/ (in Russian).
5. Goryainov V.A., Kaabak M.M., Babenko N.N. et al. Vaccination of patients with chronic renal failure before and after transplantation. Terapevticheskiy Arkhiv. 2015; 87 (12): 32–35. DOI: 10.17116/terarkh2015871232-35 (in Russian).
6. Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine. 2018; 36 (2): 202–206. DOI: 10.1016/j.vaccine.2017.11.078.
7. Ignatova G.L., Antonov V.N. An impact of vaccination on bronchial and systemic inflammation in patients with chronic obstructive pulmonary disease and ischemic heart disease. Terapevticheskiy Arkhiv. 2017; 89 (3): 29–33. DOI: 10.17116/terarkh201789329-33 (in Russian).
8. Ignatova G.L., Antonov V.N. Epidemiology of chronic respiratory diseases under vaccination against pneumococcal infection. Pul'monologiya. 2017; 27 (3): 376–383. DOI: 10.18093/0869-0189-2017-27-3-376-383 (in Russian).
9. Hoshi S.L., Kondo M., Okubo I. Economic evaluation of immunisation programme of 23-Valent Pneumococcal Polysaccharide vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate vaccine in the list for single-dose subsidy to the elderly in Japan. PLoS One. 2015; 10 (10): e0139140. DOI: 10.1371/journal.pone.0139140.
10. Wasserman M., Sings H.L., Jones D. et.al. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Rev. Vaccines. 2018; 17 (1): 71–78. DOI: 10.1080/14760584.2018.1409116.
11. The MRC breathlessness scale addapted from Fletcher C.M. Discussion on the diagnosis of pulmonary emphysema. J. Proc. R. Soc. Med. 1952; 45 (9): 576–586.
12. ATS Committee on proficiency standards for clinical pulmonary function laboratories. Am. J. Respir. Crit. Care Med. 2002; 166 (1): 111–117. DOI: 10.1164/ajrccm.166.1.at1102.
Review
For citations:
Ignatova G.L., Antonov V.N. Efficacy analysis of five-year experience of vaccination with conjugate pneumococcal vaccine in patients with chronic obstructive pulmonary disease. PULMONOLOGIYA. 2018;28(2):185-192. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-2-185-192
Views:
4313
Email this article 